Publications

Found 6 results
Filters: Author is Stockwell, Brent R  [Clear All Filters]
Journal Article
Liu, H., Forouhar, F., Lin, A. J., Wang, Q., Polychronidou, V., Soni, R. Kumar, Xia, X., and Stockwell, B. R. (2022) Small-molecule allosteric inhibitors of GPX4. Cell Chem Biol. 10.1016/j.chembiol.2022.11.003
Reglero, C., Dieck, C. L., Zask, A., Forouhar, F., Laurent, A. P., Lin, W. - H. W., Albero, R., Miller, H. I., Ma, C., Gastier-Foster, J. M., Loh, M. L., Tong, L., Stockwell, B. R., Palomero, T., and Ferrando, A. A. (2022) Pharmacological inhibition of NT5C2 reverses genetic and non-genetic drivers of 6-MP resistance in acute lymphoblastic leukemia. Cancer Discov. 10.1158/2159-8290.CD-22-0010
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., Tran, T. H., Akkiraju, H., Brown, L. M., Nandakumar, R., Cremers, S., Yang, W. Seok, Tong, L., Olive, K. P., Ferrando, A., and Stockwell, B. R. (2017) Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 168, 878-889.e29
Iketani, S., Forouhar, F., Liu, H., Hong, S. Jung, Lin, F. - Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., and Ho, D. D. (2021) Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun. 12, 2016
Liu, H., Iketani, S., Zask, A., Khanizeman, N., Bednarova, E., Forouhar, F., Fowler, B., Hong, S. Jung, Mohri, H., Nair, M. S., Huang, Y., Tay, N. E. S., Lee, S., Karan, C., Resnick, S. J., Quinn, C., Li, W., Shion, H., Xia, X., Daniels, J. D., Bartolo-Cruz, M., Farina, M., Rajbhandari, P., Jurtschenko, C., Lauber, M. A., McDonald, T., Stokes, M. E., Hurst, B. L., Rovis, T., Chavez, A., Ho, D. D., and Stockwell, B. R. (2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 13, 1891
Liu, H., Forouhar, F., Seibt, T., Saneto, R., Wigby, K., Friedman, J., Xia, X., Shchepinov, M. S., Ramesh, S. Kumar, Conrad, M., and Stockwell, B. R. (2022) Characterization of a patient-derived variant of GPX4 for precision therapy. Nat Chem Biol. 18, 91-100